Irritable bowel syndrome

Abstract

Within the literature, it appears evident that neither a univariate etiologic model nor a single-agent treatment approach is sufficient to address the many diagnostic, assessment, and therapeutic challenges posed by irritable bowel syndrome (IBS). Various scientific advances have been made over the past 5 years, particularly in the areas of nonpharmacologic management of IBS. However, further collaboration between scientists and clinicians from multiple disciplines is strongly encouraged.

Lactobacillus rhamnosus GG supernatant upregulates serotonin transporter expression in intestinal epithelial cells and mice intestinal tissues

“…Irritable bowel syndrome is one of the most frequent lower gastrointestinal tract disorders resulting in abdominal pain or discomfort accompanied by altered bowel habits, including alterations in stool frequency and/or form or appearance, especially disordered defecation . Irritable bowel syndrome can be subtyped according to the predominant bowel‐movement type as C‐IBS, D‐IBS, and IBS with alternating symptoms of both constipation and diarrhea.…”

Serotonin transporter gene promoter region polymorphisms and serotonin transporter expression in the colonic mucosa of irritable bowel syndrome patients

“…Irritable bowel syndrome (IBS) is a frequent disorder of the lower gastrointestinal tract with characteristic abdominal pain or discomfort accompanied by altered bowel habits, including alterations in stool frequency and/or form or appearance, especially disordered defecation. [1][2][3][4][5][6][7] IBS can be sub-typed according to the predominant bowel movement type: IBS with constipation (C-IBS), IBS with diarrhea (D-IBS), and IBS with alternating symptoms of both constipation and diarrhea (A-IBS). 8,9 Despite intensive research, the complicated and multifactorial pathogenesis underlying IBS is not completely understood.…”